Outcome of patients with diffuse large B-cell lymphoma and
testicular involvement - real world data

J 2025

Outcome of patients with diffuse large B-cell lymphoma and testicular involvement - real world data

MOCIKOVA, Heidi; Andrea JANÍKOVÁ; Alice SYKOROVA; Vit PROCHAZKA; Jan PIRNOS et al.

Základní údaje

Originální název

Outcome of patients with diffuse large B-cell lymphoma and testicular involvement - real world data

Autoři

Vydání

Annals of Hematology, New York, Springer, 2025, 0939-5555

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.400 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00140337

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Diffuse large B-cell lymphoma; Testicular involvement; Orchiectomy; Rituximab; CNS relapse

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 2. 2026 08:38, Mgr. Tereza Miškechová

Anotace

V originále

Patients with testicular lymphoma are at an increased risk of central nervous system (CNS) disease. Optimal strategy for CNS relapse prevention is unknown. We analyzed treatment strategies, cumulative incidence of CNS relapse and prognosis in 229 patients with diffuse large B-cell lymphoma (DLBCL) and testicular involvement: 157 primary testicular lymphomas (PTL) in clinical stages IE/IIE and 72 patients in advanced stages (T-DLBCL) IIIE/IV. Treatments for PTL vs. T-DLBCL included: rituximab-based chemotherapy (80.9% vs. 90.3%), orchiectomy (94.3% vs. 65.3%) and contralateral testicular irradiation (59.8% vs. 44.4%). Majority (84.3%) received CNS prophylaxis with similar rates of prophylactic methotrexate (intravenous 19.1% vs. 16.6%, intrathecal 40.8% vs. 40.4%, or both 24.2% vs. 27.8%) between PTL and T-DLBCL (p = 0.89). Median follow-up was 51.8 months. CNS relapses occurred in 14 (6.1%) of 63 relapsing patients. The 5-year cumulative incidence of CNS relapse in PTL was 4.5% and in T-DLBCL 12.1%. Median time to CNS relapse was 21.9 months. In univariate analyses, orchiectomy was the single significant factor associated with lower risk of CNS relapse in PTL (HR = 0.11 [95% CI, 0-0.124], p = 0.001). Rituximab significantly reduced CNS relapse risk in T-DLBCL (HR = 0.1002, p = 0.0005). Median progression-free survival (PFS) and overall survival (OS) following CNS relapse was dismal in T-DLBCL compared to PTL (PFS 1.6 vs. 37.8 months, p = 0.04 and OS 2.3 vs. 37.8 months, p = 0.05). This study confirmed a favorable impact of rituximab in prevention of CNS relapse in T-DLBCL. Methotrexate prophylaxis did not alter CNS relapse risk. Prognosis of CNS relapse is particularly poor in T-DLBCL.

Citovat

MOCIKOVA, Heidi; Andrea JANÍKOVÁ; Alice SYKOROVA; Vit PROCHAZKA; Jan PIRNOS; Juraj DURAS; Katerina KOPECKOVA; Katerina STEINEROVA; Robert PYTLIK; Petra BLAHOVCOVA; David ŠÁLEK; Tomas KOZAK; Veronika BACHANOVA a David BELADA. Outcome of patients with diffuse large B-cell lymphoma and testicular involvement - real world data. Annals of Hematology. New York: Springer, 2025, roč. 104, č. 1, s. 675-684. ISSN 0939-5555. Dostupné z: https://doi.org/10.1007/s00277-024-06025-y.

@article{2446185,
   author = {Mocikova, Heidi and Janíková, Andrea and Sykorova, Alice and Prochazka, Vit and Pirnos, Jan and Duras, Juraj and Kopeckova, Katerina and Steinerova, Katerina and Pytlik, Robert and Blahovcova, Petra and Šálek, David and Kozak, Tomas and Bachanova, Veronika and Belada, David},
   article_location = {New York},
   article_number = {1},
   doi = {https://doi.org/10.1007/s00277-024-06025-y},
   keywords = {Diffuse large B-cell lymphoma; Testicular involvement; Orchiectomy; Rituximab; CNS relapse},
   language = {eng},
   issn = {0939-5555},
   journal = {Annals of Hematology},
   title = {Outcome of patients with diffuse large B-cell lymphoma and testicular involvement - real world data},
   url = {https://link.springer.com/article/10.1007/s00277-024-06025-y},
   volume = {104},
   year = {2025}
}

TY  - JOUR
ID  - 2446185
AU  - Mocikova, Heidi - Janíková, Andrea - Sykorova, Alice - Prochazka, Vit - Pirnos, Jan - Duras, Juraj - Kopeckova, Katerina - Steinerova, Katerina - Pytlik, Robert - Blahovcova, Petra - Šálek, David - Kozak, Tomas - Bachanova, Veronika - Belada, David
PY  - 2025
TI  - Outcome of patients with diffuse large B-cell lymphoma and testicular involvement - real world data
JF  - Annals of Hematology
VL  - 104
IS  - 1
SP  - 675-684
EP  - 675-684
PB  - Springer
SN  - 09395555
KW  - Diffuse large B-cell lymphoma
KW  - Testicular involvement
KW  - Orchiectomy
KW  - Rituximab
KW  - CNS relapse
UR  - https://link.springer.com/article/10.1007/s00277-024-06025-y
N2  - Patients with testicular lymphoma are at an increased risk of central nervous system (CNS) disease. Optimal strategy for CNS relapse prevention is unknown. We analyzed treatment strategies, cumulative incidence of CNS relapse and prognosis in 229 patients with diffuse large B-cell lymphoma (DLBCL) and testicular involvement: 157 primary testicular lymphomas (PTL) in clinical stages IE/IIE and 72 patients in advanced stages (T-DLBCL) IIIE/IV. Treatments for PTL vs. T-DLBCL included: rituximab-based chemotherapy (80.9% vs. 90.3%), orchiectomy (94.3% vs. 65.3%) and contralateral testicular irradiation (59.8% vs. 44.4%). Majority (84.3%) received CNS prophylaxis with similar rates of prophylactic methotrexate (intravenous 19.1% vs. 16.6%, intrathecal 40.8% vs. 40.4%, or both 24.2% vs. 27.8%) between PTL and T-DLBCL (p = 0.89). Median follow-up was 51.8 months. CNS relapses occurred in 14 (6.1%) of 63 relapsing patients. The 5-year cumulative incidence of CNS relapse in PTL was 4.5% and in T-DLBCL 12.1%. Median time to CNS relapse was 21.9 months. In univariate analyses, orchiectomy was the single significant factor associated with lower risk of CNS relapse in PTL (HR = 0.11 [95% CI, 0-0.124], p = 0.001). Rituximab significantly reduced CNS relapse risk in T-DLBCL (HR = 0.1002, p = 0.0005). Median progression-free survival (PFS) and overall survival (OS) following CNS relapse was dismal in T-DLBCL compared to PTL (PFS 1.6 vs. 37.8 months, p = 0.04 and OS 2.3 vs. 37.8 months, p = 0.05). This study confirmed a favorable impact of rituximab in prevention of CNS relapse in T-DLBCL. Methotrexate prophylaxis did not alter CNS relapse risk. Prognosis of CNS relapse is particularly poor in T-DLBCL.
ER  -

MOCIKOVA, Heidi; Andrea JANÍKOVÁ; Alice SYKOROVA; Vit PROCHAZKA; Jan PIRNOS; Juraj DURAS; Katerina KOPECKOVA; Katerina STEINEROVA; Robert PYTLIK; Petra BLAHOVCOVA; David ŠÁLEK; Tomas KOZAK; Veronika BACHANOVA a David BELADA. Outcome of patients with diffuse large B-cell lymphoma and testicular involvement - real world data. \textit{Annals of Hematology}. New York: Springer, 2025, roč.~104, č.~1, s.~675-684. ISSN~0939-5555. Dostupné z: https://doi.org/10.1007/s00277-024-06025-y.

Přehled o publikaci